Platelet Dysfunction in Type 1 Diabetes: Stressing the Thromboxanes

Overview

Journal Diabetes

Specialty Endocrinology

Date 2016 Jan 23

PMID 26798121

Citations 7

Authors

Jaclyn A Wisinski

Michelle E Kimple

Affiliations

Soon will be listed here.

Citing Articles

Non-Traditional Pathways for Platelet Pathophysiology in Diabetes: Implications for Future Therapeutic Targets.

Sagar R, Ajjan R, Naseem K Int J Mol Sci. 2022; 23(9).

PMID: 35563363 PMC: 9104718. DOI: 10.3390/ijms23094973.

Hematological abnormalities among adults with type 1 diabetes mellitus at the University of Gondar Comprehensive Specialized Hospital.

Getawa S, Adane T SAGE Open Med. 2022; 10:20503121221094212.

PMID: 35492887 PMC: 9047808. DOI: 10.1177/20503121221094212.

Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Bosco O, Vizio B, Gruden G, Schiavello M, Lorenzati B, Cavallo-Perin P Int J Mol Sci. 2021; 22(13).

PMID: 34210000 PMC: 8269076. DOI: 10.3390/ijms22137032.

Multidirectional Effects of Tormentil Extract on Hemostasis in Experimental Diabetes.

Marcinczyk N, Golaszewska A, Gromotowicz-Poplawska A, Misztal T, Strawa J, Tomczyk M Front Pharmacol. 2021; 12:682987.

PMID: 34025439 PMC: 8131833. DOI: 10.3389/fphar.2021.682987.

Agonist-independent Gα activity negatively regulates beta-cell compensation in a diet-induced obesity model of type 2 diabetes.

Schaid M, Green C, Peter D, Gallagher S, Guthery E, Carbajal K J Biol Chem. 2020; 296:100056.

PMID: 33172888 PMC: 7948463. DOI: 10.1074/jbc.RA120.015585.

References

Harding S, Sommerfield A, Sarma J, Twomey P, Newby D, Frier B . Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis. 2004; 176(2):321-5. DOI: 10.1016/j.atherosclerosis.2004.05.008. View

Creager M, Luscher T, Cosentino F, Beckman J . Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003; 108(12):1527-32. DOI: 10.1161/01.CIR.0000091257.27563.32. View

Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E . The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012; 10(7):1220-30. DOI: 10.1111/j.1538-7836.2012.04723.x. View

de Ferranti S, de Boer I, Fonseca V, Fox C, Golden S, Lavie C . Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014; 37(10):2843-63. PMC: 4170130. DOI: 10.2337/dc14-1720. View

Spectre G, Arnetz L, Ostenson C, Brismar K, Li N, Hjemdahl P . Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011; 106(3):491-9. DOI: 10.1160/TH11-04-0216. View

Orchard T, Costacou T, Kretowski A, Nesto R . Type 1 diabetes and coronary artery disease. Diabetes Care. 2006; 29(11):2528-38. DOI: 10.2337/dc06-1161. View

Hu H, Li N, Ekberg K, Johansson B, Hjemdahl P . Insulin, but not proinsulin C-peptide, enhances platelet fibrinogen binding in vitro in Type 1 diabetes mellitus patients and healthy subjects. Thromb Res. 2002; 106(2):91-5. DOI: 10.1016/s0049-3848(02)00054-3. View

Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A . Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation. 2003; 107(25):3199-203. DOI: 10.1161/01.CIR.0000074205.17807.D0. View

Vignini A, Moroni C, Nanetti L, Raffaelli F, Cester A, Gabrielli O . Alterations of platelet biochemical and functional properties in newly diagnosed type 1 diabetes: a role in cardiovascular risk?. Diabetes Metab Res Rev. 2011; 27(3):277-85. DOI: 10.1002/dmrr.1173. View

10.

Alessandrini P, McRae J, Feman S, FitzGerald G . Thromboxane biosynthesis and platelet function in type I diabetes mellitus. N Engl J Med. 1988; 319(4):208-12. DOI: 10.1056/NEJM198807283190404. View

11.

Luscher T, Creager M, Beckman J, Cosentino F . Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003; 108(13):1655-61. DOI: 10.1161/01.CIR.0000089189.70578.E2. View

12.

Yngen M, Ostenson C, Hu H, Li N, Hjemdahl P, Wallen N . Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia. 2004; 47(3):537-540. DOI: 10.1007/s00125-004-1352-4. View

13.

Zaccardi F, Rizzi A, Petrucci G, Ciaffardini F, Tanese L, Pagliaccia F . In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. Diabetes. 2015; 65(2):503-9. DOI: 10.2337/db15-0936. View

14.

Schlingemann R, van Noorden C, Diekman M, Tiller A, Meijers J, Koolwijk P . VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care. 2013; 36(6):1629-34. PMC: 3661842. DOI: 10.2337/dc12-1951. View

15.

Tarnow I, Michelson A, Barnard M, Frelinger 3rd A, Aasted B, Jensen B . Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009; 20(7):513-9. DOI: 10.3109/09537100903221001. View